CN115737820A - Medicine for improving cognitive impairment after epilepsy - Google Patents
Medicine for improving cognitive impairment after epilepsy Download PDFInfo
- Publication number
- CN115737820A CN115737820A CN202211429074.8A CN202211429074A CN115737820A CN 115737820 A CN115737820 A CN 115737820A CN 202211429074 A CN202211429074 A CN 202211429074A CN 115737820 A CN115737820 A CN 115737820A
- Authority
- CN
- China
- Prior art keywords
- parts
- cognitive impairment
- epilepsy
- traditional chinese
- improving cognitive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 70
- 206010015037 epilepsy Diseases 0.000 title claims abstract description 41
- 208000028698 Cognitive impairment Diseases 0.000 title claims abstract description 37
- 208000010877 cognitive disease Diseases 0.000 title claims abstract description 37
- 229940079593 drug Drugs 0.000 title abstract description 11
- 239000000654 additive Substances 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 230000000996 additive effect Effects 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims abstract description 11
- 238000004806 packaging method and process Methods 0.000 claims abstract description 9
- 241001080798 Polygala tenuifolia Species 0.000 claims abstract description 8
- 241000239226 Scorpiones Species 0.000 claims abstract description 8
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 8
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 8
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 7
- 238000004140 cleaning Methods 0.000 claims abstract description 5
- 238000001035 drying Methods 0.000 claims abstract description 4
- 238000007873 sieving Methods 0.000 claims abstract description 4
- 230000001954 sterilising effect Effects 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 229940123511 Excitatory amino acid receptor antagonist Drugs 0.000 claims description 12
- 239000003963 antioxidant agent Substances 0.000 claims description 12
- 235000006708 antioxidants Nutrition 0.000 claims description 12
- 230000000508 neurotrophic effect Effects 0.000 claims description 12
- 239000003194 amino acid receptor blocking agent Substances 0.000 claims description 11
- 230000003078 antioxidant effect Effects 0.000 claims description 11
- 241000489492 Arisaema Species 0.000 claims description 7
- 210000000941 bile Anatomy 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000008213 purified water Substances 0.000 claims description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 241000893536 Epimedium Species 0.000 claims description 6
- 235000018905 epimedium Nutrition 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 3
- 244000194101 Ginkgo biloba Species 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 229930003451 Vitamin B1 Natural products 0.000 claims description 3
- 229930003779 Vitamin B12 Natural products 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 3
- 239000000428 dust Substances 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 229920001903 high density polyethylene Polymers 0.000 claims description 3
- 239000004700 high-density polyethylene Substances 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 229960003495 thiamine Drugs 0.000 claims description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 3
- 235000010374 vitamin B1 Nutrition 0.000 claims description 3
- 239000011691 vitamin B1 Substances 0.000 claims description 3
- 235000019163 vitamin B12 Nutrition 0.000 claims description 3
- 239000011715 vitamin B12 Substances 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 235000008599 Poria cocos Nutrition 0.000 claims 1
- 244000197580 Poria cocos Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 241001619461 Poria <basidiomycete fungus> Species 0.000 abstract description 8
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 description 4
- 208000000044 Amnesia Diseases 0.000 description 3
- 208000031091 Amnestic disease Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 230000006986 amnesia Effects 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 241000243684 Lumbricus Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 231100000895 deafness Toxicity 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000022540 Consciousness disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000208966 Polygala Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000522620 Scorpio Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011361 granulated particle Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000009490 scorpio Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine (a 5 IA) for improving cognitive impairment after epilepsy, which relates to the technical field of medicines and comprises 13-5 parts of ginsenoside Rb, 15-18 parts of polygala tenuifolia, 10-12 parts of earthworm, 3-6 parts of scorpion, 4-8 parts of rhizoma acori graminei, 3-6 parts of white poria and 2-4 parts of an additive in parts by weight; the preparation method of the medicine for improving cognitive impairment after epilepsy comprises the steps of respectively cleaning the traditional Chinese medicine components; sterilizing the cleaned traditional Chinese medicine components at high temperature; crushing the traditional Chinese medicine components, sieving the crushed traditional Chinese medicine components with a 200-mesh sieve, and mixing the crushed traditional Chinese medicine components to obtain a mixture; adding the additive into the mixture, and continuously mixing; granulating the mixture, and drying at 120 deg.C to make the water content not higher than 8%; packaging under sterile environment to obtain the desired medicine; the medicine provided by the invention has the advantages that the effect of improving cognitive impairment after epilepsy is improved by adding a plurality of traditional Chinese medicine components, the medicine is non-toxic and harmless to take, and the safety is improved.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a medicine for improving cognitive impairment after epilepsy.
Background
Epilepsy (epilepsy) is a chronic disease of transient cerebral dysfunction caused by sudden abnormal discharge of cerebral neurons, the clinical manifestations of the epilepsy are complex and diverse due to the difference of the initiation part and the transmission mode of the abnormal discharge, and can be manifested as paroxysmal motor, sensation, autonomic nerve, consciousness and mental disorder, long-term epilepsy usually causes certain cognitive impairment to patients, cognition is the process that human brain receives external information, and the external information is processed and converted into internal psychological activity, so as to acquire knowledge or apply knowledge, and the process comprises the aspects of memory, language, visual space, execution, calculation, understanding judgment and the like, the cognitive impairment refers to the impairment of one or more cognitive functions, and influences the daily or social abilities of individuals, and the cognitive impairment after epilepsy is mostly treated by medicines;
the existing treatment medicine has insignificant treatment and administration effects on cognitive impairment of patients, insufficient safety of medicine administration, toxic action after long-term administration, certain influence on body health, high medicine preparation cost and the like; to this end, we propose a drug that ameliorates cognitive impairment after epilepsy.
Disclosure of Invention
The main object of the present invention is to provide a medicament for improving cognitive impairment after epilepsy, which solves the problems set forth in the background above.
In order to achieve the purpose, the invention adopts the technical scheme that: a medicine (a 5 IA) for improving cognitive impairment after epilepsy comprises, by weight, 13-5 parts of ginsenoside Rb, 15-18 parts of polygala tenuifolia, 10-12 parts of earthworm, 3-6 parts of scorpion, 4-8 parts of rhizoma acori graminei, 3-6 parts of white poria and 2-4 parts of additives.
The additive comprises excitatory amino acid receptor antagonist, neurotrophic agent and antioxidant, and the ratio of excitatory amino acid receptor antagonist, neurotrophic agent and antioxidant is 0.8: 1.2: 1.
The excitatory amino acid receptor antagonist comprises 3, 5-dimethyl-1-amino-adamantane hydrochloride, the neurotrophic agent comprises folic acid, vitamin B12 and vitamin B1, the antioxidant comprises vitamin E, vitamin C and a ginkgo biloba preparation.
The medicine also comprises 3-6 parts of arisaema cum bile, 2-5 parts of calculus bovis factitius, 2-6 parts of epimedium, 2-4 parts of fructus alpiniae oxyphyllae and 35 parts of purified water by weight.
A preparation method of a medicine for improving cognitive impairment after epilepsy comprises the following steps:
s1: cleaning the traditional Chinese medicine components respectively, removing dust and impurities, and naturally draining;
s2: sterilizing the cleaned Chinese medicinal components at 150-180 deg.C for 20 min;
s3: based on the steps, crushing the traditional Chinese medicine components, sieving the crushed traditional Chinese medicine components with a 200-mesh sieve, and mixing the crushed traditional Chinese medicine components to obtain a mixture;
s4: adding the additive into the mixture, and continuously mixing for 8-12min, and continuously heating to 45-55 deg.C during mixing process to obtain further mixture;
s5: granulating the mixture, and drying at 120 deg.C to make the water content not higher than 8%;
s6: packaging in a sterile environment to obtain the medicine for improving cognitive impairment after epilepsy.
In the S1, the traditional Chinese medicine components are firstly soaked when being cleaned, and the soaking time is 1.5-2h.
The addition sequence of the additives in the S4 is a neurotrophic agent, an excitatory amino acid receptor antagonist and an antioxidant in sequence.
The diameter of the granules granulated by the mixture in the S5 is 0.5cm.
The packaging form of the S6 traditional Chinese medicine comprises aluminum film packaging or HDPE plastic bottles formed by cold stamping.
The invention has the following beneficial effects:
the medicine for improving the cognitive impairment after the epilepsy provided by the invention improves the effect of improving the cognitive impairment after the epilepsy by adding a plurality of traditional Chinese medicine components, and has no toxic or harmful effect when being taken, high safety and strong adaptability.
The medicine for improving cognitive impairment after epilepsy provided by the invention has the advantages of simple and efficient preparation method, strong controllability, controllable cost and high popularization value.
Drawings
FIG. 1 is a flow chart of a preparation method of the medicine for improving cognitive impairment after epilepsy.
Detailed Description
In order to make the technical means, the creation characteristics, the achievement purposes and the effects of the invention easy to understand, the invention is further described with the specific embodiments.
Example 1
Please refer to fig. 1: a medicine for improving cognitive impairment after epilepsy comprises, by weight, 13-5 parts of ginsenoside Rb, 15-18 parts of polygala tenuifolia, 10-12 parts of lumbricus, 3-6 parts of scorpion, 4-8 parts of rhizoma acori graminei, 3-6 parts of poria alba and 2-4 parts of additives.
The additive comprises excitatory amino acid receptor antagonist, neurotrophic agent and antioxidant, and the ratio of excitatory amino acid receptor antagonist, neurotrophic agent and antioxidant is 0.8: 1.2: 1.
Excitatory amino acid receptor antagonists including 3, 5-dimethyl-1-amino-adamantane hydrochloride, neurotrophic agents including folic acid, vitamin B12 and vitamin B1, antioxidants including vitamin E, vitamin C and ginkgo biloba preparations.
The medicine also comprises 3-6 parts of arisaema cum bile, 2-5 parts of calculus bovis factitius, 2-6 parts of epimedium, 2-4 parts of fructus alpiniae oxyphyllae and 35 parts of purified water by weight.
In the invention, the polygala has the functions of soothing nerves, benefiting intelligence, eliminating phlegm and reducing swelling, and is used for insomnia, dreaminess, amnesia, palpitation, absentmindedness and the like caused by imbalance between heart and kidney; lumbricus has effects of clearing heat, arresting convulsion, dredging collaterals, relieving asthma, and promoting diuresis, and can be used for treating hyperpyrexia, unconsciousness, convulsive epilepsy, convulsion, arthralgia, cough and asthma due to lung heat, oliguria, edema, and hypertension; the Scorpio has certain effects of relieving convulsion and epilepsy, calming endogenous wind, relieving spasm, removing toxic substances, resolving hard mass, dredging collaterals, and relieving pain; rhizoma Acori Graminei has effects of eliminating dampness, promoting appetite, inducing resuscitation, eliminating phlegm, refreshing mind and improving intelligence, and can be used for treating epigastric fullness, no hunger, vomiting, dysentery, coma, epilepsy, amnesia, deafness, qi regulating, blood circulation promoting, pathogenic wind dispelling, dampness removing, epilepsy, phlegm syncope, fever, coma, amnesia, qi block, deafness, vexation, stomach pain, abdominal pain, arthralgia due to wind-cold-dampness, superficial infection, toxic swelling, and traumatic injury; the Poria has effects in promoting diuresis, eliminating dampness, invigorating spleen, regulating stomach function, calming heart, and tranquilizing mind.
A preparation method of a medicine for improving cognitive impairment after epilepsy comprises the following steps:
s1: cleaning the traditional Chinese medicine components respectively, removing dust and impurities, naturally draining water, and soaking the traditional Chinese medicine components firstly when cleaning for 1.5-2h;
s2: sterilizing the cleaned Chinese medicinal components at 150-180 deg.C for 20 min;
s3: based on the steps, crushing the traditional Chinese medicine components, sieving the crushed traditional Chinese medicine components with a 200-mesh sieve, and mixing the crushed traditional Chinese medicine components to obtain a mixture;
s4: adding additives into the mixture, and continuously mixing for 8-12min, continuously heating to 45-55 deg.C during mixing process to obtain further mixture, wherein the additives are sequentially neurotrophic agent, excitatory amino acid receptor antagonist and antioxidant;
s5: granulating the mixture, and drying at 120 deg.C to make the water content not higher than 8%, wherein the granulated particle diameter is 0.5cm;
s6: the medicine for improving cognitive impairment after epilepsy is obtained after packaging in a sterile environment, and the packaging form comprises an aluminum film package formed by cold stamping or an HDPE plastic bottle.
Example 2
A medicine for improving cognitive impairment after epilepsy comprises, by weight, 13 parts of ginsenoside Rb, 15 parts of polygala tenuifolia, 10 parts of earthworm, 3 parts of scorpion, 4 parts of rhizoma acori graminei, 6 parts of white poria, 4 parts of an additive, 6 parts of arisaema cum bile, 2 parts of calculus bovis factitius, 6 parts of herba epimedii, 4 parts of fructus alpiniae oxyphyllae and 35 parts of purified water.
The preparation method is the same as example 1.
Example 3
A medicine for improving cognitive impairment after epilepsy comprises 15 parts of ginsenoside Rb, 16 parts of polygala tenuifolia, 11 parts of earthworm, 4 parts of scorpion, 5 parts of rhizoma acori graminei, 4 parts of white poria, 3 parts of additive, 4 parts of arisaema cum bile, 3 parts of calculus bovis artifactus, 3 parts of epimedium, 3 parts of fructus alpiniae oxyphyllae and 35 parts of purified water in parts by weight.
The preparation method is the same as example 1.
Example 4
A medicine for improving cognitive impairment after epilepsy comprises, by weight, 14 parts of ginsenoside Rb, 17 parts of polygala tenuifolia, 11 parts of earthworm, 5 parts of scorpion, 6 parts of rhizoma acori graminei, 5 parts of white poria, 3 parts of an additive, 5 parts of arisaema cum bile, 4 parts of calculus bovis artifactus, 5 parts of epimedium, 3 parts of fructus alpiniae oxyphyllae and 35 parts of purified water.
The preparation method is the same as example 1.
Example 5
A medicine for improving cognitive impairment after epilepsy comprises 15 parts of ginsenoside Rb, 18 parts of polygala tenuifolia, 12 parts of earthworm, 6 parts of scorpion, 8 parts of rhizoma acori graminei, 6 parts of white poria, 4 parts of additive, 5 parts of arisaema cum bile, 5 parts of artificial bezoar, 6 parts of epimedium, 4 parts of fructus alpiniae oxyphyllae and 35 parts of purified water by weight.
The preparation method is the same as example 1.
The patients 150 with corresponding symptoms were selected as 5 groups, which are respectively designated as group a, group B, group C, group D and group E, wherein group a used the drug prepared in example 2 of the present invention, group B used the drug prepared in example 3 of the present invention, group C used the drug prepared in example 4 of the present invention, group D used the drug prepared in example 5 of the present invention, group E used the commercially available general therapeutic drugs, and after the same administration duration and administration dosage of the patients, the patients were subjected to condition testing using the simple mental condition examination (MMSE) method and the cognitive function screening scale (CASI) method, and the results of the testing scores are shown in the following table:
table one is a comparison of the detection scores of 5 groups of drugs after use:
| group of | A | B | C | D | E |
| MMSE (minute) | 26 | 25 | 27 | 29 | 20 |
| CASI (minute) | 27 | 25 | 27 | 28 | 18 |
The above table shows that the medicine prepared by the embodiment of the invention has an obvious improvement effect on the cognitive impairment of a patient after the patient uses the medicine, has a better use effect than the commercially available therapeutic medicine, and has higher popularization value.
The foregoing shows and describes the general principles and broad features of the present invention and advantages thereof. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, which are described in the specification and illustrated only to illustrate the principle of the present invention, but that various changes and modifications may be made therein without departing from the spirit and scope of the present invention, which fall within the scope of the invention as claimed. The scope of the invention is defined by the appended claims and equivalents thereof.
Claims (9)
1. A medicine for improving cognitive impairment after epilepsy is characterized by comprising 13-5 parts of ginsenoside Rb, 15-18 parts of polygala tenuifolia, 10-12 parts of earthworm, 3-6 parts of scorpion, 4-8 parts of rhizoma acori graminei, 3-6 parts of poria cocos and 2-4 parts of additives in parts by weight.
2. The medicament for improving cognitive impairment after epilepsy according to claim 1, wherein: the additive comprises excitatory amino acid receptor antagonist, neurotrophic agent and antioxidant, and the ratio of the excitatory amino acid receptor antagonist, the neurotrophic agent and the antioxidant is 0.8: 1.2: 1.
3. The medicament for improving cognitive impairment after epilepsy according to claim 2, wherein: the excitatory amino acid receptor antagonist comprises 3, 5-dimethyl-1-amino-adamantane hydrochloride, the neurotrophic agent comprises folic acid, vitamin B12 and vitamin B1, the antioxidant comprises vitamin E, vitamin C and a ginkgo biloba preparation.
4. The medicament for improving cognitive impairment after epilepsy according to claim 1, wherein: the medicine also comprises 3-6 parts of arisaema cum bile, 2-5 parts of calculus bovis factitius, 2-6 parts of epimedium, 2-4 parts of fructus alpiniae oxyphyllae and 35 parts of purified water by weight.
5. A preparation method of a medicine for improving cognitive impairment after epilepsy is characterized by comprising the following steps:
s1: cleaning the traditional Chinese medicine components respectively, removing dust and impurities, and naturally draining;
s2: sterilizing the cleaned Chinese medicinal components at 150-180 deg.C for 20 min;
s3: based on the steps, crushing the traditional Chinese medicine components, sieving the crushed traditional Chinese medicine components with a 200-mesh sieve, and mixing the crushed traditional Chinese medicine components to obtain a mixture;
s4: adding the additive into the mixture, and continuously mixing for 8-12min, and continuously heating to 45-55 deg.C during mixing process to obtain further mixture;
s5: granulating the mixture, and drying at 120 deg.C to make the water content not higher than 8%;
s6: the medicine which is required to improve cognitive impairment after epilepsy is obtained after packaging in a sterile environment.
6. The agent for improving cognitive impairment after epilepsy according to claim 5, wherein: in the S1, the traditional Chinese medicine components are firstly soaked when being cleaned, and the soaking time is 1.5-2h.
7. The agent for improving cognitive impairment after epilepsy according to claim 5, wherein: the addition sequence of the additives in the S4 is neurotrophic agent, excitatory amino acid receptor antagonist and antioxidant.
8. The agent for improving cognitive impairment after epilepsy according to claim 5, wherein: the diameter of the granules granulated by the mixture in the S5 is 0.5cm.
9. The agent for improving cognitive impairment after epilepsy according to claim 5, wherein: the packaging form of the S6 traditional Chinese medicine comprises aluminum film packaging or HDPE plastic bottles formed by cold stamping.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211429074.8A CN115737820A (en) | 2022-11-15 | 2022-11-15 | Medicine for improving cognitive impairment after epilepsy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211429074.8A CN115737820A (en) | 2022-11-15 | 2022-11-15 | Medicine for improving cognitive impairment after epilepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115737820A true CN115737820A (en) | 2023-03-07 |
Family
ID=85371335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211429074.8A Pending CN115737820A (en) | 2022-11-15 | 2022-11-15 | Medicine for improving cognitive impairment after epilepsy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115737820A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1340302A (en) * | 2000-08-30 | 2002-03-20 | 北京莱福赛茵科技开发有限责任公司 | Nutritive health-care food for supplementing nucleic acid and its preparing process |
| CN102743401A (en) * | 2012-07-15 | 2012-10-24 | 浙江大学 | Application of panaxadiol saponins fraction in preparing medicine for preventing epilepsia |
| CN106389740A (en) * | 2016-09-13 | 2017-02-15 | 王全峰 | Composition for preventing and/or delaying old people with mild cognitive impairment and use method thereof |
| CN107397853A (en) * | 2017-09-05 | 2017-11-28 | 河南中医药大学 | A kind of Chinese medicine for treating epilepsy non-acute stage of attack |
| CN107854620A (en) * | 2017-11-10 | 2018-03-30 | 上海市静安区闸北中心医院(上海长征医院闸北分院) | The Chinese medicine composition of cognition dysfunction and its application after a kind of improvement brain damage |
-
2022
- 2022-11-15 CN CN202211429074.8A patent/CN115737820A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1340302A (en) * | 2000-08-30 | 2002-03-20 | 北京莱福赛茵科技开发有限责任公司 | Nutritive health-care food for supplementing nucleic acid and its preparing process |
| CN102743401A (en) * | 2012-07-15 | 2012-10-24 | 浙江大学 | Application of panaxadiol saponins fraction in preparing medicine for preventing epilepsia |
| CN106389740A (en) * | 2016-09-13 | 2017-02-15 | 王全峰 | Composition for preventing and/or delaying old people with mild cognitive impairment and use method thereof |
| CN107397853A (en) * | 2017-09-05 | 2017-11-28 | 河南中医药大学 | A kind of Chinese medicine for treating epilepsy non-acute stage of attack |
| CN107854620A (en) * | 2017-11-10 | 2018-03-30 | 上海市静安区闸北中心医院(上海长征医院闸北分院) | The Chinese medicine composition of cognition dysfunction and its application after a kind of improvement brain damage |
Non-Patent Citations (1)
| Title |
|---|
| 陈敏: ""祛痰定痫汤治疗癫痫 30例临床观察"", 《上海中医药杂志》, vol. 43, no. 12, pages 39 - 40 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107126485B (en) | Traditional Chinese medicine composition for assisting in improving sleep and preparation method and application thereof | |
| CN103446534B (en) | Drug for treating psychosis | |
| CN1112836A (en) | Meicinal prepn. "Kexianling" for curing epilepsy | |
| CN103520505A (en) | Traditional Chinese medicine preparation for treating neurasthenia and preparation method thereof | |
| CN100528214C (en) | Capsule for treating epilepsia and its preparing method | |
| CN103690623A (en) | Medicated wine for treating traumatic injury | |
| CN104998205A (en) | Traditional Chinese medicine for treating falling sickness mental disturbance | |
| CN103566199B (en) | A kind of Chinese medicine preparation for the treatment of post cerebral traumatic syndrome | |
| CN115737820A (en) | Medicine for improving cognitive impairment after epilepsy | |
| CN104524188A (en) | Medicament for treating vascular dementia and preparation method of medicament | |
| CN112741890B (en) | Traditional Chinese medicine composition for treating vertigo and preparation method thereof | |
| CN1843441A (en) | Rheumatism-eliminating collaterals-dredging externally applied plaster | |
| CN106728598B (en) | A kind of Chinese medicine for treating various types encephalopathy and peripheral nerve disease | |
| CN1380071A (en) | Chinese medicine for curing psychosis and epilepsy | |
| CN112826901A (en) | Medicine for quickly relieving senile dementia symptoms | |
| CN100339113C (en) | Chinese medicine capsule for treating epilepsy | |
| Jiang | Clinical observation on Tui-pushing the Large Intestine Meridian plus point sticking at Tianshu (ST 25) in prevention of post-stroke constipation | |
| CN104740210B (en) | A kind of Chinese medicine and preparation method for the treatment of qi stagnation and blood stasis type craniocerebral trauma syndrome | |
| CN106491732A (en) | The pharmaceutical composition for the treatment of nervous headache and preparation method | |
| CN108210758B (en) | Traditional Chinese medicine composition for treating mental diseases and preparation method and application thereof | |
| CN103977272B (en) | A kind of Chinese medicine for treating epilepsy and preparation method thereof | |
| Huanga et al. | Clinical Observation of the Dispelling Turbid Qi and Stopping Nausea and Vomit Decoction in Prevention of Nausea and Vomiting in Chemotherapy with Cisplatin | |
| CN104887985A (en) | Traditional Chinese medicine composition for treating walking corpse syndrome | |
| CN101972452B (en) | Medicament for treating cerebral trauma associated tardive cranial nerve dysfunction | |
| CN117919363A (en) | Traditional Chinese medicine composition for treating sleep disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |